Inhibition of proteases as a novel therapeutic strategy in the treatment of metabolic, inflammatory and functional diseases of the gastrointestinal tract

Drug Discovery Today

Volumn 18, Issue 15-16, 2013, Pages 708-715

  Sałaga, Maciej ^a   Sobczak, Marta ^a   Fichna, Jakub ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; ACETORPHAN; BESTATIN; CODEINE; CORTICOSTEROID; DELTA OPIATE RECEPTOR; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIPROTIN A; DIPROTIN B; ENDORPHIN; ER 319711 15; GLUCAGON LIKE PEPTIDE 2; KAPPA OPIATE RECEPTOR; LOPERAMIDE; METFORMIN; MORPHINE; MU OPIATE RECEPTOR; N [1 [(2,2 DIMETHYL 1,3 DIOXOLAN 4 YL)METHOXYCARBONYL] 2 PHENYLETHYL]PHENYLALANYL BETA ALANINE; PEPPERMINT OIL; PEPTIDOMIMETIC AGENT; PROBIOTIC AGENT; PROTEINASE; PROTEINASE INHIBITOR; SAXAGLIPTIN; SITAGLIPTIN; THIORPHAN; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ABDOMINAL PAIN; ACUPUNCTURE; AMINO ACID SEQUENCE; ANALGESIC ACTIVITY; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DEGRADATION; ENTERITIS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; FUNCTIONAL DISEASE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; GLUCAGON RELEASE; GROWTH REGULATION; HOMEOSTASIS; HUMAN; IC 50; INFLAMMATORY DISEASE; INSULIN RELEASE; INTESTINE INNERVATION; INTESTINE MUCOSA; IRRITABLE COLON; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERISTALSIS; PROTEINASE INHIBITION; REVIEW; SMOOTH MUSCLE CONTRACTILITY; SYNAPTIC MEMBRANE; SYNAPTOSOME;

ANIMALS; GASTROINTESTINAL DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; PROTEASE INHIBITORS; TREATMENT OUTCOME;

EID: 84881163458     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.03.004     Document Type: Review

References (50)

1. G. Horvath Endomorphin-1 and endomorphin-2: pharmacology of the selective endogenous mu-opioid receptor agonists Pharmacol. Ther. 88 2000 437 463 (Pubitemid 32406060)
2. N. Dietis Opioid receptor subtypes: fact or artifact? Br. J. Anaesth. 107 2011 8 18
3. J. Hughes Identification of two related pentapeptides from the brain with potent opiate agonist activity Nature 18 1975 577 580
4. B.M. Cox Opioid activity of a peptide, beta-lipotropin-(61-91), derived from beta-lipotropin Proc. Natl Acad. Sci. U.S.A. 73 1976 1821 1823
5. A. Goldstein Dynorphin-(1-13), an extraordinarily potent opioid peptide Proc. Natl. Acad. Sci. USA 76 1979 6666 6670 (Pubitemid 10166229)
6. J.E. Zadina A potent and selective endogenous agonist for the mu-opiate receptor Nature 3 1997 499 502 (Pubitemid 27164076)
7. M. Sobczak Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives J. Gastroenterol. 2013 10.1007/s00535-013-0753-x
8. C. Sakurada Degradation of endomorphin-2 at the supraspinal level in mice is initiated by dipeptidyl peptidase. IV. An in vitro and in vivo study Biochem. Pharmacol. 15 2003 653 661 (Pubitemid 37281284)
9. R. Shane Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase IV Brain Res. 9 1999 278 286 (Pubitemid 29231321)
10. I. Szatmari Influence of degradation on binding properties and biological activity of endomorphin 1 Biochem. Biophys. Res. Commun. 15 2001 771 776 (Pubitemid 32924796)
11. A. Peter Liquid chromatographic study of the enzymatic degradation of endomorphins, with identification by electrospray ionization mass spectrometry J. Chromatogr. A 18 1999 39 48 (Pubitemid 29332622)
12. S. Collins, and M. Verma-Gandhu The putative role of endogenous and exogenous opiates in inflammatory bowel disease Gut 55 2006 756 757 (Pubitemid 43764538)
13. C. Bunchorntavakul, and K.R. Reddy Pruritus in chronic cholestatic liver disease Clin. Liver Dis. 16 2012 331 346
14. J.P. Headrick Non-analgesic effects of opioids: cardiovascular effects of opioids and their receptor systems Curr. Pharm. Des. 18 2012 6090 6100
15. S. Husain Non-analgesic effects of opioids: neuroprotection in the retina Curr. Pharm. Des. 18 2012 6101 6108
16. P.Y. Cheng Role of mu 1- and delta-opioid receptors in modulation of fetal EEG and respiratory activity Am. J. Physiol. 265 1993 R433 R438
17. H. Chen Phosphinic derivatives as new dual enkephalin-degrading enzyme inhibitors: synthesis, biological properties, and antinociceptive activities J. Med. Chem. 6 2000 1398 1408 (Pubitemid 30212580)
18. C.H. McIntosh Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul. Pept. 15 2005 159 165 (Pubitemid 40380916)
19. U. Bank Outside or inside: role of the subcellular localization of DP4-like enzymes for substrate conversion and inhibitor effects Biol. Chem. 392 2011 169 187
20. S. Ansorge Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions Clin. Chem. Lab. Med. 47 2009 253 261
21. S. Ansorge Novel aspects of cellular action of dipeptidyl peptidase IV/CD26 Biol. Chem. 392 2011 153 168
22. J. Fichna Mu-opioid receptor ligands lack receptor subtype selectivity in the aequorin luminescence-based calcium assay Chem. Biol. Drug Des. 70 2007 247 253 (Pubitemid 47305398)
23. J. Fichna The novel endomorphin degradation blockers Tyr-Pro-DClPhe-Phe- NH (EMDB-1) and Tyr-Pro-Ala-NH (EMDB-2) prolong endomorphin-2 action in rat ileum in vitro Chem. Biol. Drug Des. 76 2010 77 81
24. H. Ban The DPP-IV inhibitor ER-319711 has a proliferative effect on the colonic epithelium and a minimal effect in the amelioration of colitis Oncol. Rep. 25 2011 1699 1703
25. M. Jia Novel aminopeptidase N (APN/CD13) inhibitors derived from chloramphenicol amine Bioorg. Med. Chem. 19 2011 5190 5198
26. Q. Li Novel potent 2,5-pyrrolidinedione peptidomimetics as aminopeptidase N inhibitors. Design, synthesis and activity evaluation Bioorg. Med. Chem. Lett. 22 2012 850 853
27. J.M. Lecomte Pharmacological properties of acetorphan, a parenterally active "enkephalinase" inhibitor J. Pharmacol. Exp. Ther. 237 1986 937 944
28. J.J. Holst Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans Am. J. Physiol. Endocrinol. Metab. 287 2004 E199 E206
29. B.J. Goldstein Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes Diabetes Care 30 2007 1979 1987 (Pubitemid 47219404)
30. B. Ahren Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin Diabetes Metab. Syndr. Obes. 3 2010 31 41
31. K. Hermansen Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin Diabetes Obes. Metab. 5 2007 733 745 (Pubitemid 47261855)
32. J. Rosenstock Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Clin. Ther. 28 2006 1556 1568 (Pubitemid 44841980)
33. H. Chahal, and T.A. Chowdhury Gliptins: a new class of oral hypoglycaemic agent QJM 100 2007 671 677 (Pubitemid 350042427)
34. N. Bohannon Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice Postgrad. Med. 121 2009 40 45
35. T. Karagiannis Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis BMJ 344 2012 E1369
36. M.S. Geier Development and resolution of experimental colitis in mice with targeted deletion of dipeptidyl peptidase IV J. Cell Physiol. 204 2005 687 692 (Pubitemid 40934665)
37. U. Bank Triggering endogenous immunosuppressive mechanisms by combined targeting of dipeptidyl peptidase IV (DPIV/CD26) and aminopeptidase N (APN/CD13) - a novel approach for the treatment of inflammatory bowel disease Int. Immunopharmacol. 20 2006 1925 1934 (Pubitemid 44855708)
38. U. Bank Inflammatory bowel diseases: multiple benefits from therapy with dipeptidyl- and alanyl-aminopeptidase inhibitors Front. Biosci. 13 2008 3699 3713 (Pubitemid 351594653)
39. R. Borzsei Inhibitory action of endomorphin-1 on sensory neuropeptide release and neurogenic inflammation in rats and mice Neuroscience 3 2008 82 88
40. D. Philippe Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation J. Clin. Invest. 111 2003 1329 1338 (Pubitemid 36554703)
41. N. Tomassini Mu and delta receptors mediate morphine effects on phagocytosis by murine peritoneal macrophages J. Neuroimmunol. 136 2003 9 16 (Pubitemid 36298839)
42. C.A. Abbott Dipeptidyl peptidases and inflammatory bowel disease Adv. Exp. Med. Biol. 575 2006 155 162
43. E.B. Andrews Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey Aliment. Pharmacol. Ther. 22 2005 935 942 (Pubitemid 41634874)
44. M. Camilleri Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation Am. J. Physiol. Gastrointest. Liver Physiol. 294 2008 G13 G19
45. J. Fichna, and M.A. Storr Brain-Gut interactions in IBS Front. Pharmacol. 3 2012 127
46. R.J. Basseri Antibiotics for the treatment of irritable bowel syndrome Gastroenterol. Hepatol. (N.Y.) 7 2011 455 493
47. L.N. Jackson Alternative medicine products as a novel treatment strategy for inflammatory bowel disease Am. J. Chin. Med. 36 2008 953 965
48. S.L. Yoon Management of irritable bowel syndrome (IBS) in adults: conventional and complementary/alternative approaches Altern. Med. Rev. 16 2011 134 151
49. S. Huighebaert Racecadotril versus loperamide: antidiarrheal research revisited Dig. Dis. Sci. 48 2003 239 250
50. M. Eberlin A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril Front. Pharmacol. 3 2012 93